ISET 24 - We are joined by investigator, Prof Ramon Varcoe (Prince of Wales Hospital, AU) to discuss the LIFE-BTK Study (NCT04227899) in consideration of the recently published position statement on BTK endovascular revascularization.
Sponsored by Abbott, LIFE-BTK is a pivotal randomized controlled trial evaluating the safety and efficacy of the everolimus-eluting Esprit BTK System for treating critical limb ischemia (CLI). 255 participants were enrolled in the trial and were randomized 2:1 to receive either the Esprit Device or balloon angioplasty.
In this interview, Prof Varcoe outlines the findings from a subgroup analysis of Rutherford class 4 or 5 LIFE-BTK patients, as well as JACC's paper, "Below-the-Knee Endovascular Revascularization: A Position Statement".
- What are the current treatment options for BTK disease, and what are the unmet needs in this area?
- What were the key findings from the subgroup analysis?
- How do the findings of LIFE-BTK figure into the recently published position statement on BTK Endovascular revascularization?
- What are some of the potentials of this technology, in terms of changing practice?
- What are the next steps?
Recorded remotely from Sydney, 2024.
Editor: Jordan Rance
Video Specialist: Oliver Miles
Support: This is an independent interview conducted by Radcliffe Cardiology.